This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for August 8th
by Zacks Equity Research
COWN, AUD, and OGN have been added to the Zacks Rank #5 (Strong Sell) List on August 8, 2022.
Organon (OGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is WisdomTree U.S. MidCap ETF (EZM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EZM
Should WisdomTree U.S. MidCap ETF (EZM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EZM
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Organon (OGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 25.95% and 3.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should WisdomTree U.S. MidCap ETF (EZM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EZM
Why Organon (OGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is WisdomTree U.S. MidCap ETF (EZM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EZM
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Why Organon (OGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.